⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 19, 2024Expert Opinion on Drug Safety

Safety of proteasome inhibitor drugs for the treatment of multiple myeloma post-marketing: a pharmacovigilance investigation based on the FDA adverse event reporting system

Dongdong Yu Ting Cheng Tong Liu Wenjun Xu Dawei Liu Jinzhi Dai Shanshan Cai Yuxiang Guan Ting Ye Xiaoyu Cheng

View at Publisher

Ask AI

Bookmark

Share

Abstract

The use of proteasome inhibitors (PIs), namely Bortezomib and Carfilzomib, revolutionized multiple myeloma (MM) treatment. Understanding their distinct adverse event (AE) profiles aids in tailored treatment plans.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yu et al. (2024) studied this question.

synapsesocial.com/papers/68e5bc3fb6db6435875547a7 https://doi.org/10.1080/14740338.2024.2393275

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Signal mining of adverse events of proteasome inhibitors in multiple myeloma based on FAERS2024 · 6 citations
2Proteasome inhibitors in multiple myeloma: 10 years laterHuman Clinical Trial · 2012 · 491 citations
3Determining the factors affecting bortezomib’s adverse events in the treatment of newly diagnosed multiple myeloma2025
4Association of posterior reversible encephalopathy syndrome with proteasome inhibitors approved for multiple myeloma: Analysis of FAERS database.2024
5Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomibOriginal Research · 2015 · 113 citations

More related papers

Proteasome inhibitors and risk of cardiovascular events in patients with multiple myeloma.2024
Proteasome inhibitors2015
Cardiovascular Adverse Events Associated With Carfilzomib, Bortezomib, and Ixazomib: A Disproportionality Analysis Using the Japanese Adverse Drug Event Report Database With Anticancer Agents as the Reference Group2026

More from Expert Opinion on Drug Safety

Long-term safety of treatment of hemophilia A: a comprehensive reviewTue,
Tolerance of methotrexate co-administered with pegloticase in patients with uncontrolled gout: overview of the findings from the mirror RCTWed,